Silva Arslanian, M.D. Richard L. Day Professor of Pediatrics Pediatric Endocrinology, Metabolism & Diabetes Mellitus University of Pittsburgh, School of Medicine Director, Pediatric Clinical & Translational Research Center Scientific Director, Center for Pediatric Research in Obesity & Metabolism Children's Hospital of Pittsburgh

If FDA Approved, Dulaglutide Provides New Treatment Option for Youth with Type 2 Diabetes

MedicalResearch.com Interview with:

Silva Arslanian, M.D. Richard L. Day Professor of Pediatrics Pediatric Endocrinology, Metabolism & Diabetes Mellitus University of Pittsburgh, School of Medicine Director, Pediatric Clinical & Translational Research Center Scientific Director, Center for Pediatric Research in Obesity & Metabolism Children's Hospital of Pittsburgh

Dr. Arslanian

Silva Arslanian, M.D.
Richard L. Day Professor of Pediatrics
Pediatric Endocrinology, Metabolism & Diabetes Mellitus
University of Pittsburgh, School of Medicine
Director, Pediatric Clinical & Translational Research Center
Scientific Director, Center for Pediatric Research in Obesity & Metabolism
Children’s Hospital of Pittsburgh

MedicalResearch.com:  What is the background for this study? 

Response: The lack of pharmacotherapeutic agents that target pathophysiological abnormalities in youth T2DM combined with the knowledge that glycemic failure rates to metformin, a recommended first-line therapy, are high in youth.

MedicalResearch.com:  What are the main findings?

1-In a DB, PC, 26-week trial of adolescents with T2DM (being treated with lifestyle modification alone or with metformin with or without basal insulin), 10<18 yrs. old with BMI >85th%, Dulaglutide showed superiority in improving HbA1C with the 0.75 and 1.5 mg weekly doses as well as the pooled-dose group. At 26 weeks, while HbA1C increased (+ 0.6%) in the placebo group, it decreased in the Dula groups (-0.6% in 0.75 mg dose group and -0.9% in the 1.5 mg dose group.
2– Similarly, Fasting plasma glucose concentrations improved with Dulaglutide.

3– Significantly more participants achieved an HbA1C <7% with Dulaglutide (51% in the Dula pooled group vs. 14% with placebo).

4– There were no differences among the groups in the change in BMI or other adiposity parameters.

MedicalResearch.com: What should readers take away from your report?

Response: If FDA approved, Dulaglutide provides a new treatment that showed efficacy and safety in youth with T2DM not well controlled with the current standard therapies. 

What recommendations do you have for future research as a result of this study? 

Response: To pursue the observation as to why there was no change in weight or BMI in these youth with T2DM unlike the adult trials.

Disclosures: Our center participated in this trial. 

Citation:

Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes

Silva A. Arslanian, M.D., Tamara Hannon, M.D., Philip Zeitler, M.D., Ph.D., Lily C. Chao, M.D., Claudia Boucher-Berry, M.D., Margarita Barrientos-Pérez, M.D., Elise Bismuth, M.D., Sergio Dib, M.D., Ph.D., Jang Ik Cho, Ph.D., and David Cox, Ph.D. for the AWARD-PEDS Investigators
June 4, 2022
DOI: 10.1056/NEJMoa2204601
https://www.nejm.org/doi/full/10.1056/NEJMoa2204601

[wysija_form id=”3″]

Jun 6, 2022 @ 3:19 pm 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. Some links may be sponsored and no links are warranted or endorsed by MedicalResearch.com or its parent company, Eminent Domains Inc. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.